Bio-Techne Corporation
TECH
Rang in aandelen
#1867
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures,... Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Aandeelprijs
$72.55
Laatst gesynchroniseerd: 2026-10-16
Marktkapitalisatie
$11.38B
Verandering (1 dag)
0.03%
Verandering (1 jaar)
17.27%
Land
US
Handel Bio-Techne Corporation (TECH)
Categorie
Healthcare
Winst voor Bio-Techne Corporation (TECH)
Winst in Jun 2026 TTM: $240.68M
Volgens de meest recente financiële verslagen van Bio-Techne Corporation bedraagt de huidige winst van het bedrijf $240.68M. In 2024 behaalde het bedrijf een winst van $185.69M, een daling ten opzichte van de winst van 2023, die $338.66M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Bio-Techne Corporation van 2000 tot 2026
Winst aan het einde van elk jaar
| Jaar | Winst | Wijzigen |
|---|---|---|
| 2026 (TTM) | $240.68M | 144.44% |
| 2025 | $98.46M | -46.97% |
| 2024 | $185.69M | -45.17% |
| 2023 | $338.66M | 12.37% |
| 2022 | $301.39M | 103.40% |
| 2021 | $148.18M | -46.41% |
| 2020 | $276.48M | 146.82% |
| 2019 | $112.02M | -11.07% |
| 2018 | $125.95M | 11.30% |
| 2017 | $113.16M | -23.27% |
| 2016 | $147.48M | -4.33% |
| 2015 | $154.16M | -4.48% |
| 2014 | $161.39M | 0.45% |
| 2013 | $160.66M | -0.95% |
| 2012 | $162.20M | -1.69% |
| 2011 | $164.98M | 5.46% |
| 2010 | $156.45M | 0.70% |
| 2009 | $155.36M | 1.00% |
| 2008 | $153.83M | 19.31% |
| 2007 | $128.93M | 15.98% |
| 2006 | $111.16M | 11.29% |
| 2005 | $99.89M | 21.02% |
| 2004 | $82.54M | 18.67% |
| 2003 | $69.56M | 84.32% |
| 2002 | $37.74M | -21.07% |
| 2001 | $47.81M | 21.30% |
| 2000 | $39.41M | 0.00% |
Winst van vergelijkbare bedrijven of concurrenten
| Bedrijf | Winst | Winstverschil | Land |
|---|---|---|---|
| $5.27B | 2,091.67% |
US
|
|
| $-3.09B | -1,382.62% |
US
|
|
| $-4.02B | -1,768.69% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 710.47% |
NL
|
